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Abstract
Background Loss of muscle mass is a co-morbidity common to a range of chronic diseases including chronic obstructive
pulmonary disease (COPD). Several systemic features of COPD including increased inflammatory signalling, oxidative stress,
and hypoxia are known to increase the expression of growth differentiation factor-15 (GDF-15), a protein associated with
muscle wasting in other diseases. We therefore hypothesized that GDF-15 may contribute to muscle wasting in COPD.
Methods We determined the expression of GDF-15 in the serum and muscle of patients with COPD and analysed the asso-
ciation of GDF-15 expression with muscle mass and exercise performance. To determine whether GDF-15 had a direct effect
on muscle, we also determined the effect of increased GDF-15 expression on the tibialis anterior of mice by electroporation.
Results Growth differentiation factor-15 was increased in the circulation and muscle of COPD patients compared with con-
trols. Circulating GDF-15 was inversely correlated with rectus femoris cross-sectional area (P< 0.001) and exercise capacity
(P< 0.001) in two separate cohorts of patients but was not associated with body mass index. GDF-15 levels were associated
with 8-oxo-dG in the circulation of patients consistent with a role for oxidative stress in the production of this protein. Local
over-expression of GDF-15 in mice caused wasting of the tibialis anterior muscle that expressed it but not in the contralateral
muscle suggesting a direct effect of GDF-15 on muscle mass (P< 0.001).
Conclusions Together, the data suggest that GDF-15 contributes to the loss of muscle mass in COPD.
Keywords Atrophy; GDF-15; Muscle mass; COPD; Electroporation
Received: 11 December 2014; Revised: 23 April 2015; Accepted: 2 November 2015
*Correspondence to: Paul Kemp, Section of Molecular Medicine, National Heart and Lung Institute, Imperial College London, SAF Building South Kensington Campus, London
SW7 2AZ, UK: Tel: +44 20 7594 1716, Email: p.kemp@imperial.ac.uk
†These authors contributed equally.
Introduction
Many patients with chronic obstructive pulmonary disease
(COPD) find that common activities of daily living become in-
creasingly difficult as they fatigue easily and lose strength.1
This reduced functional capacity is a consequence of a reduc-
tion in the quantity of muscle and the oxidative capacity of the
muscle. In addition to an impaired quality of life, both the re-
duction in strength and oxidative capacity are associated with
an increase in mortality.2,3 Consequently, the mechanisms and
factors regulating muscle mass are of significant interest.
Growth differentiation factor-15 (GDF-15) is a stress re-
sponsive growth regulator that is elevated in a number of
diseases including heart failure,4 pulmonary arterial hyperten-
sion,5,6 and diabetes7 as well as in patients on the intensive
care unit.8 This member of the transforming growth factor-β
(TGF-β) family is associated with mortality in heart failure,4
and recent studies demonstrate that serum GDF-15 levels
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are a predictor of all-cause mortality in elderly individuals.9,10
The mechanism linking the protein to mortality is not clear,
but some evidence suggests that GDF-15 may promote
muscle wasting perhaps providing such a link. For example,
we showed that in patients admitted to the intensive care unit
following heart surgery, plasma GDF-15 levels remained ele-
vated in patients who showed significant muscle wasting
7 days after surgery but not in those whose muscle mass did
not fall.11 Importantly, we also found that myotubes treated
with GDF-15 showed a reduction in diameter confirming
atrophy. Furthermore, muscle wasting in mice implanted with
GDF-15-expressing tumours was prevented by treating the
mice with an anti-GDF-15 antibody.12 In this latter study, pair
feeding experiments suggested that this muscle wasting
resulted from a suppression of appetite—a feature common
in the later stages of chronic diseases including COPD.
The biological stresses that can elevate GDF-15 include
hypoxia,13 oxidative stress,14 and increased inflammatory
cytokines,15 all features relevant in the pathogenesis of
COPD. We hypothesized that patients with COPD would have
elevated GDF-15 and that the levels of this growth factor
would be inversely associated with muscle mass. We also hy-
pothesized that the effects of increased GDF-15 on muscle
mass would be both directly on the muscle and indirectly
through appetite suppression.
Methods
Study participants
Ethical approval was obtained, and all participants provided
written informed consent prior to study testing within
the Royal Brompton & Harefield NHS Foundation Trust
(original cohort and controls; ‘RBH cohort’) or at St George’s
Healthcare NHS Trust (‘SGH cohort’ REC 10/H0721/75). Stable
COPD patients were diagnosed according to Global Initiative
in Chronic Obstructive Lung Disease (GOLD) guidelines16 and
recruited from outpatient clinics. Controls were recruited via
an ethically approved database (REC H/H1102/36). Exclusion
criteria for all participants included a physician diagnosis of
heart, renal or liver failure, significant neurological or
musculoskeletal limitation to mobility, and for patients, exac-
erbation within the past 4weeks. Specimens from the RBH
cohort and controls were previously used for our investigation
of the role of Klotho.17
Measurements included spirometry—we report the FEV1
expressed as per cent predicted (FEV1%pred),
18 plethys-
mographic lung volumes (RV/TLC),19,20 carbon monoxide dif-
fusing capacity (KCO) (CompactLab system; Jaeger, Wurzburg,
Germany),19 modified medical research council dyspnoea
score (MMRC),21 six minute walk distance (6MW) or
incremental shuttle walk distance (ISW),22 health status
(St George’s Respiratory Questionnaire (SGRQ) or COPD as-
sessment test (CAT)23), fat free mass and fat free mass
index (FFMI),24 dominant leg quadriceps strength expressed
normalized to body mass index (QMVC/BMI),25 rectus femoris
cross-sectional area (RFCSA), and daily step count.
26 The 6MW,
RV/TLC, KCO, and SGRQ data were only available in the RBH
cohort, while ISW and CAT data were only available in the
SGH cohort.
Sample collection
All participants underwent venesection prior to other testing.
A vastus lateralis percutaneous needle biopsy was performed
as previously described.27 All biological samples were stored
at 80°C prior to being analysed as a batch.
Molecular analysis
SerumGDF-15 [QUANTIKINE© (R&D Systems Inc.Minneapolis,
MN, USA)] and 8-oxo-dG (Trevigen, Gaithersburg, MD, USA)
levels were measured by enzyme-linked immunosorbent assay.
Serum 8-oxo-dG measurements were limited to the RBH
cohort. Muscle was homogenized, and cDNA was derived as
described previously.27 Human and mouse muscle mRNA ex-
pression was determined by real-time quantitative PCR (qPCR)
as previously described28 using the primers described in the
Supporting Information (Table E2) and normalizing the data
to RPLPO. Analysis of data from the RBH cohort was not per-
formed blinded, analysis of the data from the SGH data was
blinded as assays were performed at Imperial by SAB, and data
were analysed at SGH by EHB.
Cloning
Full-lengthmurine GDF-15 cDNAwas sub-cloned into pGEMT by
PCR from an IMAGE clone (Source Bioscience, Nottingham, UK)
sequenced then shuttled into pCAGGS to generate pC-GDF-15.
The pC-GDF-15 and empty pCAGGs were amplified using
JM109 bacteria and purified using EndoFree Mega kit (Qiagen,
Hilden, Germany) according to manufacturer’s instructions.
Plasmids were eluted in sterile dH2O.
Animal experiments
Mouse experiments were approved by the Royal Veterinary
College Ethical Review Process (ERP-A-2010-WS01) and were
licenced by the UK Secretary of State for the Home Office as
Project License PPL 70/6797. Sample size was estimated from
previous experiments as the minimum likely to yield a sig-
nificant result. The animals used were male C57Bl/6 mice
(24.9 ± 0.8 g) that were 8weeks of age at the start of the
GDF-15 promotes muscle atrophy in COPD 437
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 436–448
DOI: 10.1002/jcsm.12096
experiment. Experiments were performed in two blocks of
eight mice generating four control and four experimental an-
imals each time to give a total of eight in each group. Animals
were randomly assigned to control or experimental groups.
No animal samples were excluded. The analyses were not
performed blinded, but all samples were analysed simulta-
neously for each experimental variable with the exception
of animal and muscle weights, which were performed in
two blocks as described previously.
Electroporation
Twenty-five microlitres of bovine hyaluronidase (0.04U/μL,
H-4272, Sigma, Poole, Dorset, UK) was injected into each tibialis
anteriormuscle of anesthetized mice as previously described.29
Mice were left to recover for 2 h at 37C and then anesthetized
with 2% isofluorane, and 25μg of plasmid (pCAGGS empty or
pCAGGS-GDF-15) at a concentration of 1μg/μL was injected
into the right tibialis anterior, and 25μg of CAGGS empty was
injected into the left tibialis anterior. Then electrodes coated
in electro-conductive cream were placed firmly around the
tibialis anterior, and a voltage of 175V/cm was applied in ten
20ms square-wave pulses at a frequency of 1Hz using a BTX
ECM 830 electroporator (BTX Harvard Apparatus, Holliston,
MA, USA).30 After electroporation, the mice were left to re-
cover at 37°C before being returned to their normal housing.
Mice were fed with normal chow and given water ad libitum
for 2weeks, after which the mice were sacrificed by cervical
dislocation. Tibialis anterior muscles were harvested and
placed upright on to small pieces of cork with a small amount
of Optimal Cutting Temperature Compound at the bottom to
fix the bottom of the tibiales anteriores onto cork and snap
frozen in liquid nitrogen-cooled isopentane.
Sectioning
Tibialis anteriormuscles were sectioned vertically from the top
towards the cork at the bottom, and 10-μm-thick sections
grouped into 12 evenly spaced levels were cut.30 Representa-
tive sections from each level were captured onto frost-free
glass slides. The subsequent 30 sections from each level were
then collected into micro-centrifuge tubes and stored at 80°C
for mRNA analysis. The slides were allowed to air dry for
30min before storage at 80°C until use. Muscle sections were
stained with haematoxylin and eosin, and random fields were
captured at ×20 magnification using an Olympus CKX41 camera
and Cell^D software (Olympus Europe, Hamburg, Germany).
Immunohistochemistry
Sections of tibialis anterior were fixed with methanol at20°C
and then washed with phosphate-buffered saline two
times. They were then incubated in 0.3% H2O2 for 20min
and blocked in goat serum before being incubated over-
night with rabbit anti-GDF-15 (biorbyt, orb49016, 1:100)
at 4 C. Following washing with phosphate-buffered saline,
the sections were incubated with biotinylated anti-rabbit
IgG (Vectastain, ZA0520, 1:200) for 30min. Sections were
washed and then incubated with avidin and biotinylated
enzyme mix (Vectastain, Elite ABC reagent PK-6100 series),
underwent further washing, and were then stained with
diaminobenzidine. Slides were mounted and imaged at
×20 magnification.
Luciferase reporter assays
Cells were cultured as described in Martin et al.31 For assays,
2.5 × 104 cells were seeded per well and incubated overnight.
The following day, cells were transfected using lipofectamine
as previously described32 using 0.4μg plasmid DNA per
well consisting of 0.2μg of (CAGA)12-luciferase plasmid,
0.1μg of pRLTK plasmid 0.1μg pcDNA3 in 20μL Opti-Mem
(Invitrogen, Carlsbad, CA, USA). The DNA was added to
20μL Opti-MEM containing 2μL lipofectamine and incubated
for 15min and then diluted in serum-free DMEM, and 200μL
of this mix was added to each well. After 4.5 h, the media was
replaced with DMEM supplemented with 10% (v/v) foetal
bovine serum. Twenty-four hours later, cells were serum
starved for 7 h and then washed and treated with serum-free
DMEM containing either GDF-15 (R&D Systems) or TGF-β1 for
16h. Luciferase activity was assayed using the Dual-Luciferase®
Reporter Assay System (Promega, Madison,WI, USA) according
to the manufacturer’s instructions.
Statistical analysis
Statistical analyses and graphical presentations were per-
formed using Aabel, GraphPad Prism 5 (GraphPad Software,
San Diego, CA, USA) or SPSS version 18 (IBM, Armonk, NY,
USA). Significance was set at a two-tailed P-value of ≤0.05.
qPCR data were log transformed; GDF-8 and GDF-15 mRNA
expressions were normalized to RPLPO expression, except
where GDF-8 and GDF-15 were compared directly. Human
data were analysed by unpaired t-tests (normally distributed
data), Mann–Whitney (non-parametrically distributed data),
or χ2 tests to compare two groups. Analysis of variance or
Kruskal–Wallis, with post-hoc correction, was used to com-
pare three groups. Normality was determined by Shapiro–
Wilk’s test. Association between variables was evaluated by
univariate and multivariate regression analysis. Results are
expressed as mean (standard deviation) or median (inter-
quartile range). Correlation analysis was performed using
Pearson’s test to look for linear relationships in the data.
Mouse data were analysed by paired t-test to analyse the effect
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of GDF-15 within animals or unpaired t-test to determine
differences between groups. P-values for Mann–Whitney
tests and t-tests are quoted to three significant figures, as
Aabel does not give accurate P-values for P< 0.001.
Results
Physiological parameters
Consistent with a diagnosis of COPD, patients had a reduced
FEV1 and KCO, and a significantly increased RV/TLC, MMRC,
and SGRQ compared with controls. RFCSA data were avail-
able for 12 controls and 38 patients (missing values were
a result of the unavailability of equipment during the pa-
tient visit) and showed that the quadriceps bulk was smaller
in the patients compared with the controls (Figure E1).
RFCSA correlated with MVC in the cohort (Figure E2). The pa-
tients had poorer exercise performance marked by 6MW
distance compared with controls (Table 1). Fibre-type pro-
portions were available from 43 COPD patients and 10 con-
trols and showed that the proportion of type II fibres was
increased in COPD patients compared with controls (COPD
65 ± 14% type II vs. control 41±17%, P< 0.001). Consistent
with previous studies,33 6MW distance was associated with
RFCSA (r=0.595, P< 0.001), lung function (FEV1, r = 0.750,
P< 0.001),34 and proportion of type II fibres in the quadriceps
(r =0.559, P< 0.001).35 All of these components were
retained as being significantly associated with 6MW distance
in a multivariate analysis.
Patients with COPD from the RBH cohort had a marked
elevation of serum GDF-15 levels compared with healthy
controls (P< 0.001; Figure 1A). In the whole cohort, GDF-15
expression was associated with RFCSA (r =0. 381, P< 0.001;
Figure 1B) and with exercise capacity (6MW, r =0.466,
P< 0.001; Figure 1C) but was not associated with BMI or
FFMI. In COPD patients alone, the association of GDF-15 with
RFCSA did not reach statistical significance (r =0.298,
P = 0.073), but the association with 6MW was retained
(r =0.297, P = 0.048). Serum GDF-15 was not associated with
type II fibre proportion.
To confirm our findings, we analysed serum samples from
a second cohort of COPD patients attending clinics at
St George’s hospital. These patients had similar lung function,
BMI, FFMI, and strength to the RBH cohort but were older
(P< 0.001) and took fewer steps per day (P = 0.021). Analysis
of these patients showed a similar association of serum
GDF-15 with RFCSA (r =0.357, P = 0.018; Figure 1D) and
was also associated with exercise capacity analysed by in-
cremental shuttle walk distance (ISW, r =0.488, P< 0.001;
Figure 1E).
To further analyse the associations of GDF-15 with clinical
parameters, the patient data from the RBH and SGH cohorts
were combined, and univariate and multivariate regression
analysis was performed. Male gender and age were associ-
ated with higher GDF-15 levels, while RFCSA QMVC/BMI,
ISW, and daily steps were negatively associated with GDF-15.
In the multivariate analysis, age, male gender, and RFCSA were
found to have independent associations with serum GDF-15
(Table 2).
We have previously described normal RFCSA values in 40
healthy individuals with a similar demographic to the present
cohort (640 (136)mm226). Using this value, we defined rectus
femoris atrophy as an RFCSA measurement two standard
Table 1 Clinical and demographic data in the different cohorts
Healthy (n=25) RBH COPD (n=50) SGH COPD (n=44) P-value
Age 64 (7) 65 (10) 71 (8)** <0.001
Gender (male : female) 16:9 28:22 28:16 0.26
Height (m) 1.70 (0.09) 1.64 (0.23) 1.69 (0.08) 0.39
Smoking pack years 0.0 (0, 0) 40 (28, 50)*** 50 (36, 67)*** <0.001
FEV1 (%pred) 106 (13) 53 (26)*** 56 (20) Not tested
KCO (%pred) 94 (14) 68 (24)** — 0.001
RV/TLC (%) 40 (17) 50 (12) — 0.001
BMI (kg/m2) 24.9 (4.4) 26.6 (6.9) 24.4 (4.5) 0.07
FFMI (kg/m2) 18.2 (3.3) 17.6 (2.8) 16.7 (2.2) 0.11
QMVC/BMI 1.38 (0.3) 1.21 (0.5) 1.22 (0.49) 0.31
MMRC 0.0 (0, 0) 2.0 (1.1)*** 1.8 (1.1)*** <0.001
SGRQ 2 (2) 46 (24)*** — <0.001
CAT — — 19.5 (7.0) —
6MWT (m) 606 (70) 392 (107)*** — <0.001
ISWT (m) — — 263 (174) —
Steps per day 10 775 (3881) 4921 (3542)*** 3172 (2067)*** <0.001
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; RBH, Royal Brompton Hospital; SD, stan-
dard deviation; SGH, St George’s Hospital.
Data are expressed as mean (SD) or median (IQR). Differences between groups were assessed by chi-square and ANOVA or Kruskal–Wallis
with post-hoc analyses by Newman–Keuls or Dunn’s multiple comparison test.
*Significant difference of P< 0.05 as compared with healthy controls.
**Significant difference of P< 0.01 as compared with healthy controls.
***Significant difference of P< 0.001 as compared with healthy controls.
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deviations below the mean (<368mm2). In both cohorts, pa-
tients with atrophy had higher serum GDF-15 than patients
without atrophy (Figure 2).
Circulating growth differentiation factor-15 levels
relate to levels of oxidative stress
Circulating GDF-15 levels are associated with oxidative stress
marked by 8-oxo-dG in patients with renal failure. We there-
fore determined whether serum 8-oxo-dG was increased in
COPD patients and if it associated with GDF-15. Serum
8-oxo-dG was not different between controls and COPD
patients (P = 0.38; Figure E3). Considering all participants in
whom 8-oxo-dG measurements were made (n = 75), there
was only a significant univariate relationship between
8-oxo-dG levels and BMI (standardized β 0.32, P = 0.005);
although there were trends towards an association between
8-oxo-dG levels with FFMI (P = 0.06), RV/TLC (P = 0.08), and
serum GDF-15 (P = 0.06), these relationships did not quite
reach statistical significance. When limiting the analysis to
COPD patients (Table E1), only BMI (standardized β 0.44;
Figure 1 Serum GDF-15 is elevated in patients with COPD and is associated with muscle size and exercise capacity. Serum levels of GDF-15 were de-
termined in patients with COPD and age-matched controls and compared with RFCSA and exercise performance in two cohorts of COPD patients.
(A) Serum GDF-15 was elevated in COPD patients (n = 46) compared with healthy controls (n = 21, Mann–Whitney, P< 0.001). (B, D) RFCSA was inversely
correlated (Pearson’s r) with serum GDF-15 in two independent cohorts of COPD patients and controls [(B) RBH patients and controls r =0.381,
P< 0.001; (D) St George’s patients only r =0.357, P = 0.018]. (C, E) Exercise capacity was inversely correlated with serum GDF-15 in two independent
cohorts of COPD patients and controls [(C) RBH patients and controls measured as 6MW, r =0.466, P< 0.001; (E) St George’s patients only, mea-
sured as ISW, r =0.488, P< 0.001]. Patients are shown as black circles, and controls are shown as open circles. COPD, chronic obstructive pulmonary
disease; GDF, growth differentiation factor; RBH, Royal Brompton Hospital.
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P = 0.002), FFMI (standardized β 0.37; P = 0.009), and serum
GDF-15 (standardized β 0.31; P = 0.03) were associated with
8-oxo-dG levels, although none of these relationships were
retained in a multivariate analysis.
Increased growth differentiation factor-15
expression is observed in the quadriceps of chronic
obstructive pulmonary disease patients
Quadriceps muscle biopsies, with sufficient tissue to evalu-
ate GDF-15 expression, were available from 22 healthy
controls and 49 COPD patients from the RBH cohort.
GDF-15 mRNA expression was higher in quadriceps biop-
sies from COPD patients than from healthy controls
(P = 0.036, Figure 3A). As GDF-8 (myostatin) is a well-
known regulator of muscle mass in disease, we determined
the expression of this TGF-β ligand in the muscle samples.
Quadriceps GDF-8 mRNA expression was also elevated
in COPD patients as compared with healthy controls
(P = 0.002, Figure 3B). Quadriceps GDF-8 and GDF-15 mRNA
showed a strong linear correlation, r = 0.59; P< 0.001
(Figure E4). There was no relationship between serum
GDF-15 concentrations and muscle GDF-15 mRNA expres-
sion (r = 0.10, P = 0.35). Both GDF-15 and GDF-8 mRNA
were inversely correlated with 6MW distance (r =0.250,
P = 0.040, and r =0.301, P = 0.012, respectively, Figure 3C
and 3D). The univariate associations with quadriceps GDF-
15 mRNA expression in COPD patients considered alone
are presented in Table 3. GDF-15 expression was not asso-
ciated with RFCSA, FFMI, and the proportion of type II
fibres in the muscle. This latter observation suggests either
that the GDF-15 expression in the muscle is not limited to
the type II fibres or that significant inter-individual
variation in GDF-15 expression obscures association with
fibre type.
Growth differentiation factor-15 causes muscle
wasting in mice
Previous studies in mice have suggested that the association
of GDF-15 with muscle atrophy is due to a reduction in appe-
tite.12 However, GDF-15 was not associated with BMI in
either cohort, raising the possibility that in our patients,
there was a direct effect of GDF-15 on muscle, which
contributed to the reduction in muscle mass to a greater ex-
tent than appetite suppression. To address this possibility,
we electroporated the tibialis anterior of a group of mice
with an expression vector for GDF-15 and the contralateral
tibialis anterior with an empty vector. To account for
systemic effects of GDF-15, we also electroporated both
tibiales anteriores of a second control set of mice with
control vector.
The expression of GDF-15 was significantly increased in
the GDF-15-electroporated muscle compared with the
control-electroporated muscle indicating successful transfec-
tion of the tissue (Table 4), and immunostaining of muscle
showed increased GDF-15 protein (Figure 5). Protein stain-
ing was particularly strong around the cells and in the
vessels suggesting that over-expression led to secretion of
the protein. There was no effect of GDF-15 on final body
Table 2 The univariate and multivariate relationships between serum GDF-15 levels and clinical parameters in COPD patients in the RBH and SGH
cohorts
Univariate regression Multiple regression
Parameter Variable
Coefficient
(95% CI)
Standardized
coefficient P
Coefficient
(95% CI)
Standardized
coefficient P
Demographics Age 58 (32, 84) 0.42 <0.001 52 (18, 88) 0.33 0.004
Gender (male) 619 (79, 1160) 0.23 0.03 818 (209, 1428) 0.30 0.009
Current smoker 644 (1199, 90) 0.24 0.02 276 (863, 311) 0.10 0.35
Smoking pack years 5 (4, 14) 0.12 0.25 — — —
Lung function FEV1 (%pred) 1 (10, 13) 0.02 0.82 — — —
KCO (%pred) 14 (5, 32) 0.23 0.14 — — —
RV/TLC (%) 25 (61, 12) 0.20 0.18 — — —
Muscle parameters BMI 25 (21, 71) 0.12 0.27 — — —
FFMI 101 (4, 205) 0.20 0.06 — — —
QMVC/BMI 617 (1185, -51) 0.22 0.03 303 (1011, 406) 0.10 0.40
RFCSA 2.7 (4.7, 0.7) 0.28 0.01 2.4 (4.6, 0.3) 0.25 0.03
Dyspnoea/health
status
MMRC 212 (33, 457) 0.18 0.09 — — —
SGRQ (RBH only) 4 (14, 22) 0.07 0.66 — — —
CAT (SGH only) 43 (9, 95) 0.25 0.10 — — —
Exercise capacity/
physical activity
6MW (RBH only) 2 (6, 2) -0.15 0.30 — — —
ISW (SGH only) 3 (5, 2) 0.49 0.001 Not included in multivariate analysis as data
not available only available in 44 patients
Steps per day 0.10 (0.19, 0.01) 0.23 0.03 0.03 (0.07, 0.13) 0.07 0.51
BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GDF, growth differentiation factor;
RBH, Royal Brompton Hospital; SGH, St George’s Hospital.
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weight (Figure 4A), and mice expressing GDF-15 in one
tibialis anterior (experimental mice) increased in weight
to the same extent as mice electroporated with control
vector in both tibiales anteriores (control mice), indicating
that there was no effect of expression of GDF-15 on growth
rate (Figure 4B). A comparison of the tibialis anterior : body
weight ratio showed that the size of control-electroporated
tibiales anteriores was independent of the expression of
GDF-15 in the contralateral tibialis anterior (Figure 4C) as
the control tibiales anteriores from the experimental mice
were not smaller than the tibiales anteriores from the
control mice, suggesting that there was no systemic effect
of GDF-15. However, GDF-15-expressing tibiales anteriores
were smaller than control-electroporated tibiales anteriores
from the same mouse (Figure 4C). Fibre size was
determined at three different levels of the muscle (levels
6–8, see Methods section, which are towards the centre
of the muscle) in the GDF-15-expressing tibialis anterior
and the contralateral muscle. GDF-15 caused a marked
reduction in fibre diameter from 39.3 ± 0.2μm to 36.6
± 0.2μm indicating that atrophy or a suppression of
regeneration had occurred in the GDF-15-expressing muscle
and a leftward shift in the distribution of fibres (Figure 5).
To determine whether GDF-15 expression had inhibited re-
generation, the number of centralized nuclei per fibre was
counted, but no difference in this assessment of regeneration
was observed (Figure E5). Analysis of gene expression failed to
show an increase in MuRF-1 or atrogin-1 (Table 4).
Gene expression in the muscle
To determine whether GDF-15 expression modified fibre
proportion, the muscle sections were stained for all myosin
isoforms, and the expression of MHCI, MHCIIa, MHCIIb, and
MHCIIx was determined by qPCR. There was a significant
reduction in the expression of MHCIIa in the GDF-15-over-
expressing muscles, but none of the other MHCs were signi-
ficantly altered. We did not see any alteration in the expres-
sion of MuRF-1 or atrogin-1 suggesting that any change in the
expression of these genes occurred prior to 14 days. Analysis
of TGF-β responsive genes showed no change in the expres-
sion of PAI-1, a reduction in the expression of Cyr61 and a
trend to a reduction in CTGF expression (Table 4) suggesting
that there was no marked activation of the classical TGF-β
signalling system by GDF-15. These observations were consis-
tent with a lack of activation of the CAGA12 luciferase
reporter by GDF-15 in myoblasts (Figure E5).
Discussion
The data are consistent with the suggestion that GDF-15
may contribute directly to the loss of muscle mass that
occurs in patients with COPD based on three main obser-
vations: firstly, that serum levels of GDF-15 are inversely
proportional to RFCSA in patients; secondly, that muscle
GDF-15 expression is elevated in COPD patients; and
thirdly, that over-expression of GDF-15 leads to a reduc-
tion in fibre size in mice. The association of circulating
GDF-15 levels with muscle mass is not unique to COPD
as GDF-15 has been associated with cancer cachexia36 in
a number of studies, and we have shown that patients
who show wasting of the rectus femoris following cardiac
surgery are exposed to a more sustained elevation of
GDF-15 than those who do not waste.11 Furthermore,
the link between GDF-15 and all-cause mortality may
reflect the effects of this growth factor on muscle
homeostasis.
Previous studies on GDF-15 in mice have suggested that
the cachectic effects of GDF-15 are a result of a central ef-
fect suppressing appetite.12 However, in our previous study,
Figure 2 GDF-15 is elevated in COPD patients with muscle atrophy. Se-
rum GDF-15 levels were compared in patients defined as having muscle
atrophy (as described in the Methods section, n = 20) and those with a
normal muscle size (n = 69) for both the RBH and St George’s cohorts. Pa-
tients with atrophy had higher serum GDF-15 levels than those without
atrophy in both cohorts (RBH, P = 0.011, and St George’s, P = 0.022,
Mann–Whitney test). COPD, chronic obstructive pulmonary disease;
GDF, growth differentiation factor; RBH, Royal Brompton Hospital;
SGH, St George’s Hospital.
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we also found that exposure of myotubes to GDF-15 causes
wasting raising the possibility of a direct effect of GDF-15
on muscle mass.11 The data presented here suggest that
suppression of appetite is not the primary cause of the as-
sociation of GDF-15 with muscle mass in COPD for two rea-
sons: firstly, in the patients, there was no association of
Figure 3 Expression of GDF-15 and myostatin is elevated in the muscle of patients with COPD. The expression of (A) GDF-15 and (B) myostatin was
determined by real-time quantitative PCR in skeletal muscle biopsies of patients (n = 49) and controls (n = 21) from the Royal Brompton Hospital cohort
as described in the Methods section. The expression of both mRNAs was higher in the patients than in the controls (GDF-15, P< 0.001; myostatin,
P< 0.001 Mann–Whitney). (C) Muscle GDF-15 expression and (D) myostatin expression were also weakly correlated with exercise capacity measured
as 6MW in this cohort (r = 0.250, P = 0.04, and r = 0.301, P = 0.012, respectively, Pearson’s r). COPD, chronic obstructive pulmonary disease;
GDF, growth differentiation factor.
Table 3 The univariate and multivariate relationships with quadriceps GDF-15 expression and other clinical parameters in COPD patients
Univariate regression
Parameter Variable Coefficient (95% CI) Standardized coefficient P
Demographics Age 0.02 (0.04, 0.01) 0.27 0.06
Gender (male) 0.05 (0.50, 0.40) 0.04 0.81
Current smoker 0.46 (0.03, 0.89) 0.30 0.04
Pack years 0.003 (0.012, 0.006) 0.09 0.52
Lung function FEV1 (%pred) 0.003 (0.012, 0.005) 0.11 0.44
KCO (%pred) 0.007 (0.014, 0.001) 0.25 0.09
RV/TLC (%) 0.01 (0.01, 0.03) 0.15 0.31
Muscle parameters BMI 0.00 (0.04, 0.03) 0.03 0.83
FFMI 0.02 (0.09, 0.06) 0.06 0.69
QMVC/BMI 0.07 (0.54, 0.40) 0.04 0.77
RFCSA 0.001 (0.002, 0.001) 0.13 0.43
Dyspnoea/health status MMRC 0.03 (0.16, 0.22) 0.05 0.72
Health status (SGRQ) 0.00 (0.01, 0.02) 0.13 0.38
Exercise capacity/physical activity Exercise (6MW) 0.00 (0.00, 0.00) 0.11 0.44
Steps per day 0.00 (0.00, 0.00) 0.15 0.33
BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GDF, growth differentiation factor.
GDF-15 promotes muscle atrophy in COPD 443
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 436–448
DOI: 10.1002/jcsm.12096
GDF-15 with BMI, and secondly, because in the mouse
model there was no apparent systemic effect of the expres-
sion of GDF-15 in one tibialis anterior on the contralateral
tibialis anterior. The difference in response of the mouse
models (implantation of a GDF-15-expressing tumour and
electroporation of a muscle) may have arisen because the
circulating concentration of GDF-15 produced by over-
expression in the tibialis anterior is lower than that pro-
duced in the tumour model and therefore insufficient to
suppress appetite. In humans, the circulating concentrations
of GDF-15 that we observed in COPD patients were lower
than those seen in some studies of colon and metastatic
prostate cancer where serum GDF-15 levels can exceed
100 ng/mL.37 These lower levels of GDF-15 may also ac-
count for the apparent lack of association of GDF-15
with BMI.
In addition to correlating with RFCSA, GDF-15 was also as-
sociated with exercise capacity in both patient cohorts.
COPD patients show a fibre shift from a predominance of
type I fibres to a predominance of type IIA fibres in the
quadriceps muscle, and this change in fibre proportion is
associated with a marked reduction in exercise capacity.38
However, GDF-15 expression was not associated with fibre
type within the muscle nor was there an association of
serum GDF-15 with fibre proportion. These data indicate
that an increase in type II fibre proportion is not the main
cause for the increase in GDF-15 expression observed and
that any effect of circulating GDF-15 on fibre proportion
is not a significant contributor to the muscle fibre propor-
tions in COPD patients. Consistent with this suggestion,
the mouse model did not show an equivalent fibre shift
but showed a trend towards a reduction in the expression
of all MHCs. However, the fibre profile of the murine tibialis
anterior is predominantly type IIX and type IIB fibres so
that any shift towards a more glycolytic profile may be hard
to identify.
The elevation of GDF-15 in COPD patients is perhaps not
surprising. Factors that elevate GDF-15 expression include
oxidative stress,14 hypoxia,13 and elevated inflammatory
cytokines,15 all of which occur in COPD. In this study, we
show that circulating GDF-15 is weakly associated with
levels of 8-oxo-dG, a marker of oxidative stress. However,
it is not possible to tell from the data whether this associ-
ation is causal.
Recently, we have shown that GDF-15 is elevated in the
serum of patients with established critical care-associated
muscle wasting. In that study, we also showed that
plasma levels of GDF-15 were inversely correlated with
muscle expression of myomiRs miR-1, and miR-499 and
that in cultured myotubes, GDF-15 could suppress the ex-
pression of miR-1.39 These miRNAs have important func-
tions in the development and maintenance of skeletal
muscle providing a mechanism by which GDF-15 may reg-
ulate muscle phenotype. Interestingly, we have also shown
that miR-1 is suppressed in the muscle of patients with
COPD and that quadriceps expression of both miR-1 and
miR-499 is directly correlated with FFMI.27 It is therefore
possible that in COPD, GDF-15 suppresses the expression
of these miRNAs to contribute to the reduction in muscle
size. We did not see a reduction in the expression of the
same miRNAs in the tibialis anterior of mice (data not
shown). However, electroporation causes a marked stimu-
lation of regeneration, and it is possible that the effects
of GDF-15 on the expression of these miRNAs are masked
by this response.
The precise mechanism by which GDF-15 may contribute
to a reduction in muscle mass in COPD patients is not clear.
The mouse data suggest that GDF-15 causes a local effect
as we observed reduced muscle size only in the muscle
electroporated with the GDF-15 expression vector. It seems
unlikely that GDF-15 inhibits regeneration as there was no
reduction in centralized nuclei in the GDF-15-expressing
muscles. Furthermore, we have previously shown that
GDF-15 causes a reduction in myotube diameter in cultured
cells and increases the expression of the ubiquitin ligases
MuRF-1 and atrogin, suggesting that it can increase atro-
phy. However, in the mice, we did not see an increase in
MuRF or atrogin, possibly because of the timescale of
changes or the complexity of the muscle response to
electroporation.
Table 4 Normalized mRNA expression in the tibiales anteriores of mice with one tibialis anterior electroporated with a GDF-15 expression vector and
the contralateral tibialis anterior electroporated with a control vector
Gene cont (log normalized expression, AU) SEM GDF-15 (log normalized expression, AU) SEM Paired t-test
GDF-15 2.68 0.12 0.62 0.11 0.002
atrogin 0.42 0.06 0.54 0.06 0.109
murf 0.77 0.05 0.87 0.04 0.151
myhc2a 0.28 0.17 0.62 0.12 0.013
myhc2x 2.20 0.06 2.25 0.06 0.699
myhc 2b 1.60 0.07 1.42 0.08 0.144
myhc I 1.80 0.16 1.94 0.18 0.484
cyr61 1.12 0.05 1.28 0.04 0.049
CTGF 1.40 0.04 1.54 0.05 0.086
PAI-1 2.29 0.14 2.32 0.07 0.867
GDF, growth differentiation factor.
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Critique of the approach
The study presents a cross-sectional study of patients showing
associations between circulating GDF-15 with RFCSA and exer-
cise capacity, and as such, the data do not show causation.
However, the observation that the same associations are
found in two independent cohorts and that over-expression
of GDF-15 in mice leads to a reduction in muscle size suggests
that the associations are robust and that GDF-15 can play a di-
rect causative role in muscle wasting. Nonetheless, a defini-
tive role for GDF-15 in the muscle wasting of COPD patients
will require the generation of a GDF-15-neutralizing antibody
that could be used to block GDF-15 function in humans.
Figure 4 Expression of GDF-15 in the skeletal muscle of mice does not reduce growth but does cause muscle wasting. Mice were electroporated
with either a control vector into both tibiales anteriores (pCAGGS1/pCAGGS2, n = 8) or a control vector into one tibialis anterior and a GDF-15 ex-
pression vector into the contralateral tibialis anterior (pCAGGS3/GDF-15, n = 8) and then left for 14 days. (A) There was no difference in the body
weight of the mice 14 days after electroporation and (B) no difference in the growth rate of the mice. (C) There was no difference in the propor-
tionate size of the tibialis anteriores in control mice (pCAGGS1 and pCAGGS2), but the GDF-15-expressing tibiales anteriores were smaller than the
control tibiales anteriores in the experimental animals (pCAGGS3 and GDF-15 P = 0.033 paired t-test). Control tibiales anteriores from the experi-
mental mice were not smaller than the tibiales anteriores from the control mice, suggesting that there was no systemic effect of GDF-15.
GDF, growth differentiation factor. TA, (Tibialis anteriores)
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Conclusions
We show that, in patients with COPD, there is an elevation of
GDF-15 that is associated with a reduction in quadriceps
mass and with a reduction in exercise capacity. We also show
that in mice, over-expression of GDF-15 causes local muscle
wasting indicating a direct role for this growth factor in the
development of muscle wasting. This mechanism is likely to
function in tandem with appetite suppression in COPD, but
the relative contribution of each mechanism to muscle
wasting remains to be established.
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